MDT-AP-0346
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 87.96000000000001
- os_event
- false
- age_years
- 4
- sex
- M
- new_clusters
- C6
- umap1_2d
- 3.764778782
- umap2_2d
- 6.277785041
- umap1_3d
- 2.116999109
- umap2_3d
- -0.214591372
- umap3_3d
- -3.801474458
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.610
- G2M_CHECKPOINT+0.510
- MITOTIC_SPINDLE+0.260
- MYC_TARGETS_V1+0.250
- DNA_REPAIR+0.240
- SPERMATOGENESIS+0.200
- WNT_BETA_CATENIN_SIGNALING+0.120
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.090
- HEDGEHOG_SIGNALING+0.070
- FATTY_ACID_METABOLISM+0.030
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- INFLAMMATORY_RESPONSE-0.380
- INTERFERON_ALPHA_RESPONSE-0.380
- INTERFERON_GAMMA_RESPONSE-0.350
- HYPOXIA-0.330
- ESTROGEN_RESPONSE_EARLY-0.300
- TNFA_SIGNALING_VIA_NFKB-0.290
- UV_RESPONSE_DN-0.280
- IL6_JAK_STAT3_SIGNALING-0.270
- P53_PATHWAY-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_Y8D1F5WW | medulloblastoma | — | 0.881 |
| 2 | BS_BSV07M7Z | medulloblastoma | — | 0.880 |
| 3 | SRR13780269 | — | cohortSC | 0.880 |
| 4 | TCGA-UY-A78N-01A-12R-A33J-07 | — | — | 0.877 |
| 5 | BS_4PH1MBGR | medulloblastoma | — | 0.874 |
| 6 | BS_G00FHF3Q | medulloblastoma | — | 0.874 |
| 7 | BS_VMEX27TN | medulloblastoma | — | 0.872 |
| 8 | MNG704 | — | — | 0.872 |
| 9 | BS_EFE4YEK3 | medulloblastoma | — | 0.871 |
| 10 | SRR8518197 | — | E | 0.869 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.610 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.510 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.250 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.090 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.070 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |